LAUSR

Simple Summary Magnetic resonance (MR) imaging had limited clinical indications in patients with thoracic malignancies in the last a few decades. However, technical advances in MR system, sequence, receiver coils with parallel imaging capability and reconstruction methods and clinical protocol adjustment including gadolinium contrast media administration make it possible to achieve MR imaging as not only morphological, but also functional and metabolic imaging tools for thoracic malignancies. Then, the Fleischner Society recommend MR imaging for lung diseases in 2020. In this review article, we focus on the MR imaging for lung cancer as well as pulmonary nodules and masses. Abstract Since the Radiology Diagnostic Oncology Group (RDOG) report had been published in 1991, magnetic resonance (MR) imaging had limited clinical availability for thoracic malignancy, as well as pulmonary diseases. However, technical advancements in MR systems, such as sequence and reconstruction methods, and adjustments in the clinical protocol for gadolinium contrast media administration have provided fruitful results and validated the utility of MR imaging (MRI) for lung cancer evaluations. These techniques include: (1) contrast-enhanced MR angiography for T-factor evaluation, (2) short-time inversion recovery turbo spin-echo sequences as well as diffusion-weighted imaging (DWI) for N-factor assessment, and (3) whole-body MRI with and without DWI and with positron emission tomography fused with MRI for M-factor or TNM stage evaluation as well as for postoperative recurrence assessment of lung cancer or other thoracic tumors using 1.5 tesla (T) or 3T systems. According to these fruitful results, the Fleischner Society has changed its position to approve of MRI for lung or thoracic diseases. The purpose of this review is to analyze recent advances in lung MRI with a particular focus on lung cancer evaluation, clinical staging, and recurrence assessment evaluation.